Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
S Urba, J Doroshow, C Cripps, F Robert… - Cancer chemotherapy …, 1992 - Springer
S Urba, J Doroshow, C Cripps, F Robert, E Velez-Garcia, B Dallaire, D Adams, R Carlson…
Cancer chemotherapy and pharmacology, 1992•SpringerA total of 19 patients with advanced squamous-cell carcinoma of the head and neck who
had not previously been exposed to chemotherapy were treated with brequinar sodium as
first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of
1,200 mg/m 2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4
toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response.
We conclude that brequinar given at this dose and on this schedule has no significant …
had not previously been exposed to chemotherapy were treated with brequinar sodium as
first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of
1,200 mg/m 2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4
toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response.
We conclude that brequinar given at this dose and on this schedule has no significant …
Abstract
A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.
Springer